A phase 2 study of pegylated liposomal doxorubicin, bortezomib, dexamethasone and lenalidomide for patients with relapsed/refractory multiple myeloma.
about
Treatment of relapsed and refractory multiple myelomaEvolving paradigms in the treatment of relapsed/refractory multiple myeloma: increased options and increased complexityPhase I/II trial assessing bendamustine plus bortezomib combination therapy for the treatment of patients with relapsed or refractory multiple myeloma.A prospective, international phase 2 study of bortezomib retreatment in patients with relapsed multiple myeloma.Phase II study of pegylated liposomal doxorubicin, low-dose dexamethasone, and lenalidomide in patients with newly diagnosed multiple myelomaA phase 2 trial of lenalidomide, bortezomib, and dexamethasone in patients with relapsed and relapsed/refractory myelomaPhase I study of olaparib in combination with liposomal doxorubicin in patients with advanced solid tumours.Lycorine Downregulates HMGB1 to Inhibit Autophagy and Enhances Bortezomib Activity in Multiple Myeloma.Management of double-refractory multiple myeloma.Current treatment landscape for relapsed and/or refractory multiple myeloma.An update on the use of lenalidomide for the treatment of multiple myeloma.Current treatment strategies with lenalidomide in multiple myeloma and future perspectives.Trial Watch: Lenalidomide-based immunochemotherapy.Mature results of MM-011: a phase I/II trial of liposomal doxorubicin, vincristine, dexamethasone, and lenalidomide combination therapy followed by lenalidomide maintenance for relapsed/refractory multiple myeloma.Safety and efficacy of pomalidomide, dexamethasone and pegylated liposomal doxorubicin for patients with relapsed or refractory multiple myeloma.
P2860
Q26749180-FE47696B-3BF5-49B7-80D0-EB63E7959EBEQ26771331-003E0793-2A60-4BA0-AE5D-D8DDDFEEE7C5Q33404348-C282E174-F23B-4E7D-9E8B-F467CCE5A17AQ33405134-A208CB4A-7948-4CC5-B9FD-9D9A7F4E3124Q33410297-DC6B3430-CB53-46AA-BC0B-707FC6BA0364Q33412684-AFE00E5B-A3A3-4A9C-830F-F0B995EE6CDCQ33416440-DBDD9515-A952-4E54-A4B1-303D9A0D7ADEQ37469859-94CCA93D-93D3-4360-AE7F-401B45C0C0C1Q38131456-529BFB16-6759-4841-9C20-AEB95B956F66Q38271032-7D03D968-D4D1-417F-B296-052379944029Q38545607-58E3E609-8872-4E21-950C-DED0D6D31328Q39524467-75DBC830-47D9-4AD0-8F07-F934A4BE0E90Q42737828-D51B5FE1-9A68-4459-8674-3E69E2250E95Q44469916-DADF7455-074D-4A13-8D2D-E533B32FE0E4Q46147631-4510D948-8ECA-4833-A374-AEA1B9D0D3B6
P2860
A phase 2 study of pegylated liposomal doxorubicin, bortezomib, dexamethasone and lenalidomide for patients with relapsed/refractory multiple myeloma.
description
2012 nî lūn-bûn
@nan
2012 թուականի Փետրուարին հրատարակուած գիտական յօդուած
@hyw
2012 թվականի փետրվարին հրատարակված գիտական հոդված
@hy
2012年の論文
@ja
2012年論文
@yue
2012年論文
@zh-hant
2012年論文
@zh-hk
2012年論文
@zh-mo
2012年論文
@zh-tw
2012年论文
@wuu
name
A phase 2 study of pegylated l ...... d/refractory multiple myeloma.
@ast
A phase 2 study of pegylated l ...... d/refractory multiple myeloma.
@en
type
label
A phase 2 study of pegylated l ...... d/refractory multiple myeloma.
@ast
A phase 2 study of pegylated l ...... d/refractory multiple myeloma.
@en
prefLabel
A phase 2 study of pegylated l ...... d/refractory multiple myeloma.
@ast
A phase 2 study of pegylated l ...... d/refractory multiple myeloma.
@en
P2093
P2860
P356
P1433
P1476
A phase 2 study of pegylated l ...... d/refractory multiple myeloma.
@en
P2093
A Cartmell
J D Hilger
J R Berenson
P2860
P2888
P304
P356
10.1038/LEU.2012.51
P577
2012-02-22T00:00:00Z
P5875
P6179
1048569379